Lupin launches strategic partnership for long-acting injectable platform

Lupin Limited announced on October 9, 2025, the launch of a strategic partnership program aimed at broadening the adoption of PrecisionSphere™, its long-acting injectable (LAI) platform developed by subsidiary Nanomi B.V. This initiative follows U.S. FDA approval for the platform's first product, validating its efficacy and safety for commercial use. The program seeks collaborations with companies looking to extend product lifecycles through longer-acting formulations.

According to Dr. Fabrice Egros, president of corporate development at Lupin, the expansion will leverage Lupin’s in-house and alliance management capabilities to accelerate the delivery of innovative LAI solutions to patients. Dr. Shahin Fesharaki, chief scientific officer, highlighted that PrecisionSphere™ offers consistent particle size and optimized drug levels, ensuring stable drug concentrations for weeks to months, unlike conventional LAI technologies.

This technology is designed to reduce injection frequency, enhancing patient convenience and compliance, and allowing healthcare professionals to control drug delivery at optimal therapeutic doses. The platform aims to lower entry barriers for advanced LAI development across various therapeutic areas, potentially extending product patent lives for partners.